HOME >> BIOLOGY >> NEWS
JCI Table of Contents, April 13, 2006

EDITOR'S PICK

Researchers resolve controversy over how COX inhibitors cause heart hazards, and offer alternative treatment strategy

Inhibitors of cyclooxygenase-2 (COX-2) were developed to relieve inflammatory pain as effectively as nonsteroidal anti-inflammatory drugs (NSAIDS), but without one of their major side effects, gastrointestinal bleeding. However, an unexpected adverse cardiovascular effect a higher incidence of myocardial infarction was subsequently detected, causing the highly publicized withdrawal of COX-2 inhibitors from the market in late 2004. A number of large, randomized, controlled trials designed to test the efficacy of different COX-2 inhibitors for a variety of indications have confirmed the cardiovascular toxicity, suggesting that this is an effect of all drugs in this class. However, just how this class of drug causes this heart hazard has remained controversial. Now, in a study appearing online on April 13 in advance of print publication in the May issue of the Journal of Clinical Investigation, Garret FitzGerald and colleagues from the University of Pennsylvania School of Medicine report how COX-2 inhibitors increase the incidence of myocardial infarction and stroke. In addition, they propose a new therapeutic approach that retains the beneficial anti-inflammatory effects of NSAIDS and COX-2 inhibitors, while avoiding their adverse cardiovascular consequences.

COX-2 inhibitors are believed to exert both their beneficial and their adverse effects by suppression of COX-2derived prostacyclin (PGI2) and prostaglandin E2 (PGE2). These substances help prevent platelet clumping in blood vessels and vessel relaxation and/or constriction, respectively. Therefore, the challenge has been to identify a mechanism whereby PGI2 and PGE2 expression can be suppressed while avoiding adverse cardiovascular events. FitzGerald and colleagues now show that selective inhibition, knockout, or mutation of COX-2, or deletion
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
13-Apr-2006


Page: 1 2 3 4 5 6

Related biology news :

1. JCI Table of Contents -- July 2, 2007
2. JCI Table of Contents: July 13, 3006
3. JCI Table of Contents, June 15 2006
4. JCI Table of contents August 1, 2005
5. JCI Table of Contents, March 1, 2005
6. ACS News Service Weekly PressPac -- April 25, 2007
7. Story tips from the Department of Energys Oak Ridge National Laboratory, April 2007
8. ACS News Service Weekly PressPac -- April 18, 2007
9. JCI table of contents -- April 19, 2007
10. Other highlights from the April 18 Journal of the National Cancer Institute
11. AGU Journal Highlights -- April 16, 2007

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/19/2019)... ... November 19, 2019 , ... The inaugural Cell & ... in New York City. The one-day event will be chaired by Dr Aiman Shalabi, ... in the space. , “We are witnessing significant innovation in cell and gene ...
(Date:11/14/2019)... , ... November 13, 2019 , ... Personalized Stem ... first patients in an FDA approved clinical trial for stem cell treatment of ... formation of the company as a subsidiary of VetStem Biopharma. , In July of ...
(Date:11/12/2019)... ... November 12, 2019 , ... G5, the ... digital advertising performance up to 25% and reduces cost-per-click by as much as ... advanced multi-touch attribution (MTA) to predict best advertising outcomes and automatically allocate daily ...
Breaking Biology News(10 mins):
(Date:11/9/2019)... ... November 08, 2019 , ... PathAI, a ... today announced the results of analyses examining the severity of nonalcoholic steatohepatitis ... selonsertib studies (STELLAR). Strong correlations were demonstrated between AI-powered and manual pathologist ...
(Date:11/5/2019)... ... 2019 , ... Ole, a German Shepherd, was demonstrating signs of osteoarthritis in April 2019. ... energy level and his willingness to play were normal, it was clear that he was ... VCA Emergency Animal Hospital and Referral Center in San Diego, California. Dr. Mullen ...
(Date:10/30/2019)... ... October 30, 2019 , ... Western University ... roles innovation and technology play in educating the next generation of health care ... opportunities and presentations by WesternU administrators and representatives of companies working with the ...
(Date:10/22/2019)... ... ... nQ Medical, Inc. of Cambridge, MA, was recognized in the top 5 ... at a showcase event yesterday in Los Angeles. nQ competed against 3,500 early-stage U.S. ... near-term growth projections to be named one of the most fundable companies in America. ...
Breaking Biology Technology:
Cached News: